

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))			Docket No. 01-531
In Re Application Of: Douglas C. Shepard			
Serial No. Unassigned	Filing Date Filed Herewith	Examiner Unassigned	Group Art Unit Unassigned
Title: MEDICAL ARTICLES HAVING ENZYMATIC SURFACES FOR LOCALIZED THERAPY			
Address to: Assistant Commissioner for Patents Washington, D.C. 20231			
37 CFR 1.97(b)			
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.			
37 CFR 1.97(c)			
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:			
<div style="margin-left: 40px;"> <input type="checkbox"/> the statement specified in 37 CFR 1.97(e); </div>			
OR			
<div style="margin-left: 40px;"> <input type="checkbox"/> the fee set forth in 37 CFR 1.17(p). </div>			

1c867 U.S. PTO
10/057596
01/24/88

U.S. PTO
10/057596
01/24/02

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))			Docket No. 01-531
In Re Application: Douglas C. Shepard			
Serial No. Unassigned	Filing Date Filed Herewith	Examiner Unassigned	Group Art Unit Unassigned
MEDICAL ARTICLES HAVING ENZYMATIC SURFACES FOR LOCALIZED THERAPY			
<p style="text-align: center;">Payment of Fee</p> <p style="text-align: center;">(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))</p> <p><input type="checkbox"/> A check in the amount of _____ is attached.</p> <p><input type="checkbox"/> The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. _____ as described below. A duplicate copy of this sheet is enclosed.</p> <p style="margin-left: 40px;"> <input type="checkbox"/> Charge the amount of _____ <input type="checkbox"/> Credit any overpayment. <input type="checkbox"/> Charge any additional fee required. </p> <div style="display: flex; justify-content: space-between;"> <div style="width: 48%;"> <p>Certificate of Transmission by Facsimile*</p> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F </div> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> _____ (Date) </div> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> _____ Signature </div> <div style="border: 1px solid black; padding: 5px;"> _____ Typed or Printed Name of Person Signing Certificate </div> </div> <div style="width: 48%;"> <p>Certificate of Mailing by ^{Express} First-Class Mail</p> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> I certify that this document and fee is being deposited <u>1/24/02</u> with the U.S. Postal Service as <u>first class</u> mail under 37 C.F.R. <u>1.8</u> and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231. </div> <div style="border: 1px solid black; padding: 5px; margin-bottom: 5px;"> Signature of Person Mailing Correspondence </div> <div style="border: 1px solid black; padding: 5px;"> Marjorie Scariati Typed or Printed Name of Person Mailing Certificate </div> </div> </div> <p style="font-size: small;">*This certificate may only be used if paying by deposit account.</p> <div style="display: flex; justify-content: space-between; margin-top: 20px;"> <div style="width: 45%;"> Signature David B. Bonham Reg. No. 34,297 Mayer Fortkort & Williams, PC 251 North Avenue West, 2nd Floor Westfield, NJ 07090 Tel.: 703-433-0510 </div> <div style="width: 45%;"> Dated: <u>Jan. 24, 2002</u> </div> </div> <p>cc:</p>			

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

01-531

Application Number

Unassigned

Applicant(s)

Douglas C. Shepard

Filing Date

Filed Herewith

Group Art Unit

Unassigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	1	4,525,456	6/25/85	Rohrbach	435	176	
	2	6,024,918	2/15/00	Hendriks et al.	422	44	
	3	6,033,719	3/7/00	Keogh	422	2.12	
	4	6,077,714	6/20/00	Spallholz et al.	436	525	

10/05/96
10/05/96
01/24/02

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	1	Senatore et al., "Fibrinolytic activity of immobilized plasminogen activator," Res Commun Chem Pathol Pharmacol 1985 Aug:49(2) 295-304, Abstract only.
	2	Forster et al., "Analysis of urokinase immobilization on the polytetrafluoroethylene vascular prosthesis," Am J Surg 1988: 156(2): 130-2, Abstract only

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

01-531

Application Number

Unassigned

Applicant(s)

Douglas C. Shepard

Filing Date

Filed Herewith

Group Art Unit

Unassigned

*EXAMINER
INITIAL

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

3

Harvey et al., "Binding of tissue plasminogen activator to vascular grafts," Thromb Haemost 1989 Feb;61(1):131-6, Abstract Only

4

Jefferies et al., "Preliminary studies with L-asparaginases bound to implantable bovine collagen heterografts: a potential long-term, sustained dosage, antitumor enzyme therapy system," Biomater Med Devices Artif Organs 1977;5(4):3337-54, Abstract Only.

5

Raghavan et al., "Degradation of oxalate in rats implanted with immobilized oxalate oxidase," FEBS Lett 1986 Jan 20;195(1-2):101-5, Abstract Only.

6

Jamie Y. Jeremy et al., "Nitric oxide and the proliferation of vascular smooth muscle cells," Cardiovascular Research 1999 Aug 15;43(3):580-94.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.